High-profile departures at Avexis raise more questions about Novartis’s acquisition, but there were plenty of red flags before the deal was sealed.
On sales per employee Abbvie and Bristol-Myers Squibb lead the big pharma pack, while Sanofi and Astrazeneca are the sector laggards.
The acquisition marked Astrazeneca’s formal embrace of biologicals. Today the Medimmune name was dropped.
Immunocore has recently been beset with multiple senior executive departures, but has managed to press on into phase I with a Glaxo-partnered asset.
Big cap medtech is hiring, largely thanks to organic growth.
Bristol-Myers Squibb has come out on top of an analysis of efficiency in big pharma. Being in immuno-oncology might have helped – but so might aggressive job cuts.
GE arrives to the spin-out party fashionably late.